The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy. This agreement follows Inbiomotion’s recent distribution partnerships for Spain and Portugal with Palex Medical, The Scientific Group for Sub-Saharan Africa and Source BioScience for United Kingdom and Ireland.
The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates. The results that demonstrate the clinical usefulness of MAF Test. were published in The Lancet Oncology (2017) and the Journal of National Cancer Institute (2021) respectively.
Thanks to this agreement, the MAF Test will also be available in Italy and could increase the survival of 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed each year.
Dr. Joël Jean-Mairet, Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital, commented, "We are thrilled to partner with SPA Farma to bring the cutting-edge MAF Test® to Italy. This collaboration represents a significant step forward in making precision 2 | 2 medicine accessible to more patients. We believe that this partnership with SPA Farma will play a crucial role in achieving these goals in the Italian market."
Comments